-
ScienceDaily
May 30, 2015, 10:25 am145 ptsBecause of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial.
Trending Today on EcoTopical
Welcome to EcoTopical Your daily eco-friendly green news aggregator.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.